Gossamer Bio (GOSS) Change in Accured Expenses (2018 - 2026)

Gossamer Bio's Change in Accured Expenses history runs 9 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 192.86% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $945000.0 (down 80.84% YoY), while the FY2024 annual figure was -$135000.0, up 83.83% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.4 million, up from $25000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $8.6 million in Q3 2024, with the low at -$5.7 million in Q2 2022.
• The 5-year median for Change in Accured Expenses is -$127000.0 (2025), against an average of $27294.1.
• Peak annual rise in Change in Accured Expenses reached 914.91% in 2024, while the deepest fall reached 1576.92% in 2024.
• Gossamer Bio's Change in Accured Expenses stood at -$2.5 million in 2022, then soared by 246.86% to $3.6 million in 2023, then tumbled by 168.53% to -$2.5 million in 2024, then jumped by 101.0% to $25000.0 in 2025, then soared by 5640.0% to $1.4 million in 2026.
• Business Quant data shows GOSS's Change in Accured Expenses at $1.4 million in Q1 2026, $25000.0 in Q4 2025, and -$388000.0 in Q3 2025.